Insider trades
Hannah Valantine, Director of BridgeBio Pharma BBIO, has filed 5 purchases and 18 sales on the open market. Over the past 12 months that comes to a net sale of $4.6M. The latest trade was on 06/23.
Hannah Valantine
Director
- Company
- BridgeBio Pharma BBIO
- First filing
- 23/01/09
- Trades
- 62 trades
- Buys / sales
- 5 / 18
- 12-month net buying
- −$4.6M
- Last trade
- 06/23
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
BBIO | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 5,004 sh2 trades | $68.25avg. | $341,523.72 | −35.1% |
CareDxCDNA | Open-market sale10b5-1 plan | 06/15 | 06/16 | 12,103 sh | $23.11 | $279,700.33 | −24.8% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 03/10 | 03/12 | 8,671 sh | $72.00 | $624,312 | −53.7% |
BBIO | Open-market sale10b5-1 plan | 02/27 | 03/03 | 25,484 sh2 trades | $67.41avg. | $1,717,750.72 | −77.3% |
BridgeBio PharmaBBIO | Open-market sale | 25/11/12 | 25/11/14 | 25,484 sh | $66.07 | $1,683,727.88 | −77.3% |
BBIO | Open-market sale | 25/06/26 | 25/06/30 | 4,707 sh4 trades | $44.05avg. | $207,328.25 | No record |
BBIO | Open-market buyAmendment | 21/12/28–21/12/29 | 25/06/30 | 4,090 sh3 trades | $13.44avg. | $54,976.4 | No record |
CareDxCDNA | Open-market sale10b5-1 plan | 25/06/18 | 25/06/23 | 10,570 sh | $19.16 | $202,521.2 | −21.3% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 25/06/10 | 25/06/11 | 4,292 sh | $40.00 | $171,680 | −70.9% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 25/03/06 | 25/03/10 | 12,875 sh | $32.58 | $419,467.5 | −87.9% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 24/02/15 | 24/02/20 | 2,915 sh | $37.75 | $110,041.25 | −62.3% |
BBIO | Open-market buy | 21/12/28 | 24/02/13 | 3,433 sh2 trades | $12.96avg. | $44,475.94 | No record |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 24/01/16 | 24/01/18 | 2,915 sh | $37.97 | $110,682.55 | −62.3% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 23/12/15 | 23/12/19 | 2,915 sh | $36.12 | $105,289.8 | −62.3% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 23/11/15 | 23/11/17 | 2,915 sh | $30.00 | $87,450 | −62.3% |
